NeuBase Therapeutics (NASDAQ:NBSE) Lowered to “Sell” at ValuEngine

Share on StockTwits

NeuBase Therapeutics (NASDAQ:NBSE) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report issued on Wednesday, ValuEngine reports.

Other equities analysts also recently issued reports about the stock. HC Wainwright initiated coverage on shares of NeuBase Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $14.00 target price on the stock. Oppenheimer began coverage on shares of NeuBase Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $14.00 target price on the stock. Finally, BTIG Research began coverage on shares of NeuBase Therapeutics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $15.00 price target on the stock.

Shares of NBSE stock opened at $6.01 on Wednesday. The stock’s 50-day moving average price is $4.96. NeuBase Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.95.

An institutional investor recently bought a new position in NeuBase Therapeutics stock. Heritage Wealth Advisors purchased a new stake in NeuBase Therapeutics (NASDAQ:NBSE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 11,000 shares of the company’s stock, valued at approximately $54,000. Heritage Wealth Advisors owned 0.06% of NeuBase Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.81% of the company’s stock.

NeuBase Therapeutics Company Profile

NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.

Further Reading: What is meant by holder of record?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

LRAD Corporation  Receives Average Recommendation of “Strong Buy” from Brokerages
LRAD Corporation Receives Average Recommendation of “Strong Buy” from Brokerages
Zacks: Analysts Expect Vaccinex Inc  to Post -$0.52 EPS
Zacks: Analysts Expect Vaccinex Inc to Post -$0.52 EPS
Zacks: Brokerages Anticipate Entasis Therapeutics Holdings Inc  Will Post Earnings of -$0.99 Per Share
Zacks: Brokerages Anticipate Entasis Therapeutics Holdings Inc Will Post Earnings of -$0.99 Per Share
Zacks: Brokerages Set $86.00 Price Target for Federal Agricultural Mortgage Corp.
Zacks: Brokerages Set $86.00 Price Target for Federal Agricultural Mortgage Corp.
Analysts Anticipate Red Lion Hotels Co.  to Post  Earnings Per Share
Analysts Anticipate Red Lion Hotels Co. to Post Earnings Per Share
Karyopharm Therapeutics Inc  CEO Sells $170,200.00 in Stock
Karyopharm Therapeutics Inc CEO Sells $170,200.00 in Stock


© 2006-2019 Ticker Report